Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on July 21, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $125.00.
A physician and a patient having a discussion in a hospital about biopharmaceutical medicines.
On July 14, Gilead Sciences, Inc. presented new data on the twice-yearly Lenacapavir (Yeztugo®) for HIV Prevention at the IAS 2025.
The company reported that new data from the PURPOSE trials showed that Lenacapavir was well-tolerated and effective across a range of populations, including lactating and pregnant women, young people, and adolescents.
The data also showed that the twice-yearly injectable PrEP was preferred compared to daily oral medication among PURPOSE trial participants.
Gilead Sciences, Inc. is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.
Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. operates in over 35 countries.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
